Bristol-Myers Squibb Collaborates with Foundation Medicine to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

March 30, 2017 Bristol-Myers Squibb Company and Foundation Medicine has announced a collaboration that leverages comprehensive genomic profiling and molecular information solutions of Foundation Medicine to identify predictive biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across clinical trials investigating cancer immunotherapies of Bristol-Myers Squibb. Biomarkers can be used to characterize a … Continue reading Bristol-Myers Squibb Collaborates with Foundation Medicine to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

Advertisements
Roche logo

Roche announces the launch of cobas HPV on the cobas 6800/8800 Systems for cervical cancer screening in markets

28 March 2017 Roche has announced the CE-IVD launch of cobas® HPV for use on the cobas® 6800/8800 Systems for cervical cancer screening. Human Papillomavirus (HPV) is a known cause of cervical cancer and is used to identify women at risk. This HPV DNA assay adds to the growing CE-IVD menu on the cobas 6800/8800 Systems, … Continue reading Roche announces the launch of cobas HPV on the cobas 6800/8800 Systems for cervical cancer screening in markets

AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody

March 3, 2017 AstraZeneca has decided to partner with Sanofi on an experimental antibody for RSV. The French pharma giant is paying €120 million upfront and up to €495 million more in development and sales milestones to buy into the program. Now, the two Big Pharmas will split R&D costs for MEDI8897, with AstraZeneca in charge of … Continue reading AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody

Otsuka Pharmaceutical Acquiring Neurovance

Mar 3, 2017 In an effort to expand the portfolio of central nervous system-based therapies, Otsuka Pharmaceutical will acquire Neurovance Inc. in a transaction that could be worth as much as $250 million. As per the deal, Otsuka subsidiary Otsuka America Inc. will pay $100 million at closing and as much as $150 million based on approval … Continue reading Otsuka Pharmaceutical Acquiring Neurovance

Incyte turns to Penn for a collaboration on next-gen cancer combos

February 23, 2017 Incyte Corporation has signed off on a multi-year deal for collaborating with scientists at the University of Pennsylvania on its next-gen combos and cancer therapies. The Abramson Cancer Center of the university will take a lead role in looking at patient selection and combination opportunities as Incyte advances its plans to develop … Continue reading Incyte turns to Penn for a collaboration on next-gen cancer combos

Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

Feb 15, 2017 Integra Lifesciences, a prominent medical device maker, has announced that it will acquire the Codman Neurosurgery business of Johnson & Johnson's (JNJ) for $1.05 billion. The Codman unit of JNJ includes a portfolio of medical devices focusing on advanced hydrocephalus, operative neurosurgery, and neuro-critical care, according to the company. During 2016, the acquired products generated approximately $370 million … Continue reading Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

February 10, 2017 Seat­tle Ge­net­ics has become the new flag car­rier for the solid tumor drug IMMU-132 of   Im­munomedics. In order to claim global rights on the drug, Seat­tle Ge­net­ics is pay­ing $300 mil­lion, and also com­mit­ting up to $1.7 bil­lion more in mile­stones. The biotech will now take the lead on a Phase III … Continue reading Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

johnson & johnson logo

Johnson & Johnson to Purchase Actelion for $30 Billion

Jan 26, 2017 Johnson & Johnson (J&J) has said that it is going to buy Swiss biotech Actelion Pharmaceuticals for $30 billion. The company also plans to spin out its research and development unit into a separate business. The deal is expected to close in mid-February. The companies said in a statement that J&J will pay $280 … Continue reading Johnson & Johnson to Purchase Actelion for $30 Billion

Eli Lilly Logo

Lilly to Acquire CoLucid Pharmaceuticals

Jan. 18, 2017 Eli Lilly and Company and CoLucid Pharmaceuticals, Inc. has announced an agreement for Lilly to acquire CoLucid for $46.50 per share or nearly $960 million. This all-cash transaction will enhance the existing portfolio of Lilly in pain management for migraine. The transaction is expected to close by the end of the first quarter of 2017. CoLucid Pharmaceuticals is a … Continue reading Lilly to Acquire CoLucid Pharmaceuticals

Lilly and Merck Expand Immuno-Oncology Collaboration

Jan. 11, 2017 Eli Lilly and Company has announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, to add a new study of LARTRUVO™ (olaratumab) of Lilly with Merck’s KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS). Especially, the U.S. Food and Drug Administration (FDA) recently approved LARTRUVO … Continue reading Lilly and Merck Expand Immuno-Oncology Collaboration